Copeland Capital Management LLC lessened its holdings in Pfizer, Inc. (NYSE:PFE) by 4.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 7,897 shares of the biopharmaceutical company’s stock after selling 365 shares during the period. Copeland Capital Management LLC’s holdings in Pfizer were worth $265,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Quantitative Systematic Strategies LLC bought a new stake in Pfizer in the second quarter worth $1,443,000. Huntington National Bank increased its position in Pfizer by 1.7% in the second quarter. Huntington National Bank now owns 1,868,974 shares of the biopharmaceutical company’s stock worth $62,779,000 after purchasing an additional 30,501 shares during the last quarter. Bridges Investment Counsel Inc. increased its position in Pfizer by 96.9% in the second quarter. Bridges Investment Counsel Inc. now owns 87,642 shares of the biopharmaceutical company’s stock worth $2,944,000 after purchasing an additional 43,140 shares during the last quarter. Private Bank & Trust Co. increased its position in Pfizer by 0.8% in the second quarter. Private Bank & Trust Co. now owns 64,124 shares of the biopharmaceutical company’s stock worth $2,154,000 after purchasing an additional 478 shares during the last quarter. Finally, Hermes Investment Management Ltd. increased its position in Pfizer by 0.6% in the second quarter. Hermes Investment Management Ltd. now owns 564,042 shares of the biopharmaceutical company’s stock worth $18,946,000 after purchasing an additional 3,473 shares during the last quarter. Institutional investors own 69.09% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Copeland Capital Management LLC Trims Position in Pfizer, Inc. (PFE)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this article can be read at https://www.thecerbatgem.com/2017/09/11/copeland-capital-management-llc-trims-position-in-pfizer-inc-pfe.html.

Several brokerages recently weighed in on PFE. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. BMO Capital Markets restated a “buy” rating and issued a $37.00 price target on shares of Pfizer in a research report on Wednesday, September 6th. Credit Suisse Group cut shares of Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research report on Thursday, July 20th. Sanford C. Bernstein set a $39.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 17th. Finally, Cowen and Company set a $43.00 price target on shares of Pfizer and gave the stock a “buy” rating in a research report on Monday, July 10th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $37.61.

Shares of Pfizer, Inc. (PFE) traded up 0.35% during mid-day trading on Monday, hitting $34.22. 6,775,563 shares of the stock were exchanged. The stock has a market cap of $203.52 billion, a price-to-earnings ratio of 25.03 and a beta of 1.00. The company has a 50-day moving average price of $33.35 and a 200-day moving average price of $33.48. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $34.75.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.02. The firm had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm’s revenue was down 1.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.64 earnings per share. Equities analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a yield of 3.75%. The ex-dividend date of this dividend was Wednesday, August 2nd. Pfizer’s payout ratio is 94.12%.

In other Pfizer news, insider Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $34.00, for a total transaction of $249,900.00. Following the transaction, the insider now owns 124,774 shares of the company’s stock, valued at $4,242,316. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 426,291 shares of company stock valued at $14,475,911. 0.06% of the stock is owned by company insiders.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.